Improving Radioimmunotherapy with a Second Antibody
Author Information
Author(s): JL Casey, DJ King, RB Pedley, JA Boden, R Boden, LC Chaplin, M Dorning, RHJ Begent
Primary Institution: Cancer Research Campaign Laboratories, Royal Free Hospital School of Medicine
Hypothesis
Can a second antibody improve the therapeutic ratio in radioimmunotherapy by reducing blood levels of radioantibodies?
Conclusion
The use of a second antibody significantly reduced blood levels of radioantibodies and improved tumor-blood ratios, although it also decreased the amount of antibody at the tumor site.
Supporting Evidence
- Administration of the second antibody produced up to a tenfold reduction in blood levels of radioantibodies.
- Despite reduced antibody levels at the tumor site, tumor-blood ratios remained superior to the control group.
- Estimated dosimetry showed lower total doses to normal tissues with the use of the second antibody.
Takeaway
This study found that giving a second antibody can help clear radioactive antibodies from the blood, making treatment safer and potentially more effective.
Methodology
Mice with human colorectal tumor xenografts were injected with yttrium-90-labelled antibodies and then given a second antibody at various time points to assess clearance and tumor-blood ratios.
Potential Biases
Potential bias in the selection of time points for administering the second antibody and measuring outcomes.
Limitations
The study primarily focused on short-term effects and did not evaluate long-term outcomes or potential side effects in humans.
Participant Demographics
Nude mice bearing human colorectal tumor xenografts.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website